Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'

Kimberly-Clark CEO Mike Hsu told CNBC's Jim Cramer that his company's planned acquisition of Tylenol maker Kenvue will create value for shareholders, even as the the pain reliever is scrutinized by the Trump administration.He also said Tylenol sales have "seen a little bit of impact, but less than you would think" from Secretary of Health and Human Services Robert F. Kennedy Jr. and President Donald Trump promoted unfounded claims linking the use of Tylenol's active ingredient, acetaminophen, during pregnan ...